Q BioMed (OTC: QBIO) is a biomedical acceleration and development company that is focused on acquiring undervalued biomedical assets. Q BioMed is dedicated to providing these target assets, strategic resources, developmental support, and expansion capital to accelerate development and, ultimately, to provide much needed products‏. The company intends to maximize risk-adjusted returns by focusing on clinical stage and innovative products where the technical, regulatory and commercial risks have been mitigated or major valuation inflections are imminent. For more information, visit the company’s website at www.qbiomed.com